<DOC>
	<DOCNO>NCT02974725</DOCNO>
	<brief_summary>To characterize safety tolerability LXH254 LTT462 combination identify recommend dose regimen .</brief_summary>
	<brief_title>Study LXH254 LTT462 NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients must advance metastatic NSCLC Presence KRAS BRAF mutation tumor tissue All patient participate clinical trial must progress follow standard therapy , opinion Investigator , effective standard therapy exist , tolerate , appropriate consider equivalent study treatment . ECOG ( Eastern Cooperative Oncology Group ) performance status â‰¤ 2 Dose expansion Group 1 : Prior treatment RAFi ( include BRAFi panRAFi ) , MEKi and/or ERKi . Group 2 : Prior treatment ERKi and/or panRAFi . History current evidence retinal vein occlusion ( RVO ) current risk factor RVO . Any medical condition would , investigator 's judgment , prevent patient 's participation clinical study due safety concern compliance clinical study procedure . Patients receive proton pump inhibitor ( PPI ) discontinue 3 day prior start study treatment duration study . Patients Gilbert 's syndrome heritable disease bile processing . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>KRAS</keyword>
	<keyword>BRAF</keyword>
	<keyword>LXH254</keyword>
	<keyword>LTT462</keyword>
	<keyword>Non-small cell lung carcinoma ( NSCLC )</keyword>
	<keyword>treatment lung cancer first metastasis</keyword>
	<keyword>lung cancer</keyword>
	<keyword>lung adenocarcinoma</keyword>
	<keyword>Large-cell lung carcinoma</keyword>
	<keyword>Non small cell lung carcinoma</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Large cell lung carcinoma</keyword>
	<keyword>Large cell lung cancer</keyword>
	<keyword>squamous cell lung carcinoma</keyword>
</DOC>